Keybanc Reiterates Buy Rating for LivaNova PLC with $92 Target

Keybanc has reiterated its buy rating for LivaNova PLC, a medical technology company listed on the NasdaqGS under the ticker LIVN. On June 22, 2026, analyst Brett Fishbin set a price target of $92. Shares of LivaNova traded at $78.5 on Monday.

What Changed in Keybanc's LivaNova Position

Keybanc maintained its buy rating for LivaNova PLC, with a new price target of $92. This reiteration suggests confidence in the company's future prospects.

Other Institutional Activity in LivaNova

Several institutional investors have made moves in LivaNova recently. BlackRock, Inc. reduced its stake by 184,614 shares, holding about 7.14 million shares valued at approximately $453.7 million, a 2.5% decrease. Primecap Management Co/CA/ also cut its holdings by 17,800 shares, ending with roughly 4.21 million shares worth $267.4 million, a 0.4% decrease. On the other hand, FMR LLC significantly boosted its position by 2,620,791 shares, bringing its total to 2.67 million shares valued at about $169.5 million, marking a substantial 5711.9% increase. AQR Capital Management LLC added 339,230 shares, increasing its stake by 15.7% to approximately 2.49 million shares worth $154.4 million.

LivaNova PLC Stock Down 0.5%

Shares of NasdaqGS:LIVN traded near $78.5 on Monday. LivaNova PLC has a market capitalization of approximately $4.31 billion. The company's P/E ratio stands at 40.1, with a forward P/E of 17.0, indicating the stock's valuation based on expected earnings. The stock has experienced a 52-week low of $41.02 and a high of $80.96. Its 50-day moving average is $69.94, while the 200-day moving average is $62.58. LivaNova's beta is 0.884, suggesting less volatility compared to the market.

Recent Earnings

LivaNova reported revenue of about $1.43 billion, with a growth rate of 14.3%. The company's net margin is 7.5%, and it has a return on equity of 9.5%. Earnings per share stand at $1.96. The next earnings report is expected on August 5, 2026.

Insider Buying and Selling at LivaNova PLC

Recent insider activity at LivaNova includes significant transactions on June 15, 2026. Chief Innovation Officer Ahmet Tezel purchased 2,965 shares. Francesco Bianchi and Seng Stacy Enxing each bought 2,383 shares. Meanwhile, Donald Zurbay sold 308 shares at an average price of $79.7. Todd Schermerhorn also acquired 4,042 shares.

Analysts Set New Price Targets

On June 22, 2026, Keybanc maintained its buy rating on LivaNova, setting a price target of $92. Other firms like Barclays and Mizuho have also maintained their ratings, with Barclays setting a hold rating and a $76 target on May 7, 2026, and Mizuho maintaining a buy rating with a $90 target.

About LivaNova PLC

LivaNova PLC is a medical technology company based in London, United Kingdom. It focuses on developing and selling medical devices and therapies, particularly in the fields of cardiopulmonary and neuromodulation. The company serves healthcare professionals and institutions across many countries, including the United States and several European nations. Led by CEO Mr. Vladimir A. Makatsaria, LivaNova employs around 3,300 people.

Bottom Line

Keybanc's reiteration of a buy rating with a $92 target highlights ongoing confidence in LivaNova's potential. Investors closely follow such analyst ratings as part of their investment decisions. However, it's important to remember that these ratings are based on past data and projections, and actual performance may vary.